Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy
April 16 2019 - 7:00AM
-Details from ongoing SUNRISE-PD Phase 2 trial of
AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral
presentations-
Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage
company developing innovative gene therapies, announced two
upcoming oral presentations and one poster presentation at the 22nd
Annual Meeting of the American Society of Gene & Cell Therapy
(ASGCT). Details from the ongoing SUNRISE-PD Phase 2 trial of
AXO-Lenti-PD for the treatment of Parkinson’s disease and the
delivery approach for the AXO-AAV-GM2 program will be shared in
oral presentations. Additionally, preclinical data related to the
AXO-AAV-GM1 program will be presented in a poster.
Details of the oral presentations are as
follows:Title: A Safe and Reliable Technique for
Central Nervous System Delivery of AAV Vectors via the Cisterna
Magna (Abstract #31) Session date/time: April 29,
2019, 10:30-10:45am ET
Title: AXO-LENTI-PD: a
second-generation lentiviral gene therapy for the treatment of
Parkinson’s Disease (Abstract #222)Session
date/time: April 30, 2019, 3:30-3:45pm ET
Details of the poster presentation are as
follows:Title: Intravenous Delivery of AAV Gene
Therapy in GM1 Gangliosidosis (Abstract #401) Session
date/time: April 30, 2019, 5:00pm ET
The ASGCT Annual Meeting will be held in
Washington, DC, April 29 - May 2, 2019. Additional information on
the meeting can be found on the ASGCT website:
http://www.asgct.org
About Axovant Gene
Therapies
Axovant, part of the Roivant family of
companies, is a clinical-stage gene therapy company focused on
developing a pipeline of innovative product candidates for
debilitating neurological and neuromuscular diseases. The company’s
current pipeline of gene therapy candidates targets GM1
gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and
Sandhoff disease), Parkinson’s disease, oculopharyngeal muscular
dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia. Axovant is focused on accelerating product
candidates into and through clinical trials with a team of experts
in gene therapy development and through external partnerships with
leading gene therapy organizations. For more information, visit
www.axovant.com.
About Roivant
Roivant Sciences aims to improve health by
rapidly delivering innovative medicines and technologies to
patients. It does this by building Vants – nimble, entrepreneurial
biotech and healthcare technology companies with a unique approach
to sourcing talent, aligning incentives, and deploying technology
to drive greater efficiency in R&D and commercialization. For
more information, please visit www.roivant.com.
Forward Looking Statements and
Information
Statements contained in this press release that
are not purely historical may be deemed to be forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Without limiting the foregoing, the use of words
such as “may,” “might,” “will,” “expect,” “plan,” and other similar
expressions are intended to identify forward-looking statements.
All forward-looking statements are based on estimates and
assumptions by Axovant’s management that, although Axovant believes
to be reasonable, are inherently uncertain. All forward-looking
statements are subject to risks and uncertainties that may cause
actual results to differ materially from those that Axovant
expected. In addition, Axovant’s business is subject to additional
risks and uncertainties, including among others, the initiation and
conduct of preclinical studies and clinical trials; the timing and
availability of data from clinical trials; the expectations for
regulatory submissions and approvals; the potential safety concerns
or profile of Axovant’s product candidates; and the availability or
commercial potential of product candidates. These statements are
also subject to a number of material risks and uncertainties that
are described in Axovant’s most recent Quarterly Report on Form
10-Q for the quarterly period ended December 31, 2018, filed with
the Securities and Exchange Commission on February 7, 2019, as
updated by its subsequent filings with the Securities and Exchange
Commission. Any forward-looking statement speaks only as of the
date on which it was made. Axovant undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
Contacts:
MediaMike BeyerSam Brown Inc.
(312) 961-2502mikebeyer@sambrown.commedia@axovant.com
InvestorsTricia
TruehartAxovant(631) 892-7014investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024